Contact information
+44 (0)1865 857253
Research groups
Ruth Coleman
MSc
Head of Statistics & Modelling Group
Ruth is the Head of Statistics and Modelling Group, responsible for the management of the unit’s statistical output, maintaining transparency and presenting results in an impartial and objective manner.
In her time in the DTU she has gained extensive experience in the design, analysis and reporting of phase 2-4 trials with a focus on large scale cardiovascular outcome trials including TECOS, EXSCEL and ACE. Outside of trial work, the group use data from both randomized controlled trials and observational studies to evaluate diabetes-related complications and mortality, and produce validated prediction models to contribute to the improvement of outcomes in people with diabetes.
Her ongoing projects include the expansion of the UKPDS Risk Engine to include estimates of both cardiovascular and microvascular disease risk, and modelling life expectancy in type 2 diabetes.
She is currently a co-investigator on the UKPDS Legacy Study and the statistical lead for the ACE trial.
Recent publications
-
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
Journal article
Adler AI. et al, (2024), Lancet
-
Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
Journal article
Morrow LM. et al, (2024), J Diabetes, 16
-
Orthostatic Hypotension, Hypertension Treatment, and Cardiovascular Disease: An Individual Participant Meta-Analysis.
Journal article
Juraschek SP. et al, (2023), JAMA, 330, 1459 - 1471
-
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Journal article
Hundertmark MJ. et al, (2023), Circulation, 147, 1654 - 1669
-
11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.
Journal article
Othonos N. et al, (2023), Nat Commun, 14